Literature DB >> 21041957

The discovery and development of analgesics: new mechanisms, new modalities.

Gillian Burgess1, Dic Williams.   

Abstract

Despite intensive research into pain mechanisms and significant investment in research and development, the majority of analgesics available to prescribers and patients are based on mechanistic classes of compounds that have been known for many years. With considerable ingenuity and innovation, researchers continue to make the best of the mechanistic approaches available, with novel formulations, routes of administration, and combination products. Here we review some of the mechanisms and modalities of analgesics that have recently entered into clinical development, which, coupled with advances in the understanding of the pathophysiology of chronic pain, will hopefully bring the promise of new therapeutics that have the potential to provide improved pain relief for those many patients whose needs remain poorly met.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041957      PMCID: PMC2966322          DOI: 10.1172/JCI43195

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  106 in total

Review 1.  Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.

Authors:  G P Miljanich
Journal:  Curr Med Chem       Date:  2004-12       Impact factor: 4.530

Review 2.  Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission.

Authors:  David J Dooley; Charles P Taylor; Sean Donevan; Douglas Feltner
Journal:  Trends Pharmacol Sci       Date:  2007-01-10       Impact factor: 14.819

Review 3.  Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets.

Authors:  Gordon Munro; Philip K Ahring; Naheed R Mirza
Journal:  Trends Pharmacol Sci       Date:  2009-09-02       Impact factor: 14.819

4.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

5.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

6.  Propentofylline attenuates allodynia, glial activation and modulates GABAergic tone after spinal cord injury in the rat.

Authors:  Young Seob Gwak; Eric D Crown; Geda C Unabia; Claire E Hulsebosch
Journal:  Pain       Date:  2008-03-18       Impact factor: 6.961

7.  Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia.

Authors:  Chun-Ying Li; Yan-Hua Song; Emiliano S Higuera; Z David Luo
Journal:  J Neurosci       Date:  2004-09-29       Impact factor: 6.167

8.  The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule.

Authors:  S B McMahon; D L Bennett; J V Priestley; D L Shelton
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

9.  Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Authors:  S G Kinsey; J Z Long; S T O'Neal; R A Abdullah; J L Poklis; D L Boger; B F Cravatt; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2009-06-05       Impact factor: 4.030

Review 10.  Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain.

Authors:  C J Woolf
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1996-03-29       Impact factor: 6.237

View more
  23 in total

Review 1.  What is this thing called pain?

Authors:  Clifford J Woolf
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

2.  Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.

Authors:  E M Hoffman; Z Zhang; M B Anderson; R Schechter; K E Miller
Journal:  Neuroscience       Date:  2011-07-28       Impact factor: 3.590

3.  A new hypertonic saline assay for analgesic screening in mice: effects of animal strain, sex, and diurnal phase.

Authors:  Yahya I Asiri; Desmond H Fung; Timothy Fung; Alasdair M Barr; Ernest Puil; Stephan K W Schwarz; Bernard A MacLeod
Journal:  Can J Anaesth       Date:  2021-02-18       Impact factor: 5.063

Review 4.  Reward and motivation in pain and pain relief.

Authors:  Edita Navratilova; Frank Porreca
Journal:  Nat Neurosci       Date:  2014-09-25       Impact factor: 24.884

5.  Effects of TrkA inhibitory peptide on cancer-induced pain in a mouse melanoma model.

Authors:  Mari Tabata; Eri Murata; Koyo Ueda; Nahoko Kato-Kogoe; Yoshihiro Kuroda; Munetaka Hirose
Journal:  J Anesth       Date:  2012-05-22       Impact factor: 2.078

6.  Gene Therapy for Pain: A Perspective.

Authors:  David J Fink; Darren Wolfe
Journal:  Pain Manag       Date:  2011-09

Review 7.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

8.  The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers.

Authors:  Elisavet K Tiaka; Nikolaos Papanas; Anastassios C Manolakis; Efstratios Maltezos
Journal:  Int J Burns Trauma       Date:  2011-09-03

9.  Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde.

Authors:  Michael J Espiritu; Justin Chen; Jaydeep Yadav; Michael Larkin; Robert D Pelletier; Jeannine M Chan; Jeevan B Gc; Senthil Natesan; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2020-08-12       Impact factor: 3.922

10.  Oxidant-induced activation of cGMP-dependent protein kinase Iα mediates neuropathic pain after peripheral nerve injury.

Authors:  Jana E Lorenz; Wiebke Kallenborn-Gerhardt; Ruirui Lu; Katharina M J Syhr; Philip Eaton; Gerd Geisslinger; Achim Schmidtko
Journal:  Antioxid Redox Signal       Date:  2014-03-05       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.